beta
IA Trial Radar

Mostrando estudos clínicos realizados em: Greater London.

Posso ajudar você a encontrar estudos clínicos em locais específicos e fornecer insights clínicos relevantes sobre condições de saúde e tratamentos.

No modo avançado, acesse ferramentas poderosas de pré-seleção, visualizações interativas e alertas personalizados por e-mail sobre atualizações dos estudos.

Nossa ferramenta de busca suporta apenas o inglês. Para pesquisa e discussão em outros idiomas, use a IA Trial Radar acima ou selecione filtros de condições médicas e locais abaixo.
67 resultados
Mostrando os 50 primeiros
 
Status (Padrão)
Ainda Não Recrutando, Em Recrutamento, Ativo, Não Recrutando
×
 
Locais
Greater London
×
 
Sexo
Todos
×
 
Tipo
Biológico
×
 
Título do estudo
Status
A Study to Investigate Multiple Sclerosis Relapse Prevention With mRNA-1195 Compared With Placebo in Participants Aged 18 to ≤55 Years NCT06735248
Em recrutamento
First-in-Human Study of ICT01 in Patients With Advanced Cancer (EVICTION) NCT04243499
Ativo, não recrutando
Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma NCT04759586
Ativo, não recrutando
MAGNITUDE: A Phase 3 Study of NTLA-2001 in Participants With Transthyretin Amyloidosis With Cardiomyopathy (ATTR-CM) NCT06128629
Em recrutamento
Testing Sacituzumab Govitecan Therapy in Patients With HER2-Negative Breast Cancer and Brain Metastases NCT04647916
Ativo, não recrutando
A Clinical Study of Calderasib (MK-1084) With Targeted Therapy and Chemotherapy in People With Colorectal Cancer (MK-1084-012/KANDLELIT-012) NCT06997497
Em recrutamento
Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic Agents NCT04739800
Ativo, não recrutandoResultados publicados
Long-Term PF-06651600 for the Treatment of Alopecia Areata (ALLEGRO-LT) NCT04006457
Ativo, não recrutandoResultados publicados
EA2176: Phase 3 Clinical Trial of Carboplatin and Paclitaxel +/- Nivolumab in Metastatic Anal Cancer Patients NCT04444921
Ativo, não recrutando
Studying Chemotherapy With or Without Panitumumab for Unresectable, Locally Advanced, or Metastatic Pancreatic Cancer Without KRAS Mutations NCT06998940
Em recrutamento
Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors NCT03866382
Em recrutamento
Pivotal 2 Study of RGX-314 Gene Therapy in Participants With nAMD (ASCENT) NCT05407636
Em recrutamento
A Study Testing the Effect of Immunotherapy (Ipilimumab and Nivolumab) in Patients With Recurrent Glioma With Elevated Mutational Burden NCT04145115
Ativo, não recrutando
Comparing the New Anti-cancer Drug Eribulin With Chemotherapy Against the Usual Chemotherapy Alone in Metastatic Urothelial Cancer NCT04579224
Ativo, não recrutando
Using Biomarkers to Help Guide Safe Immunotherapy Discontinuation in Patients With Unresectable Stage IIIB-IV Melanoma, The PET-Stop Trial NCT04462406
Ativo, não recrutando
Gemcitabine and Cisplatin Without Cystectomy for Patients With Muscle Invasive Bladder Urothelial Cancer and Select Genetic Alterations NCT03609216
Em recrutamento
Study of Pembrolizumab (MK-3475) Versus Placebo in Participants With Esophageal Carcinoma Who Are Receiving Chemotherapy and Radiation Therapy (MK-3475-975/KEYNOTE-975) NCT04210115
Ativo, não recrutando
Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast Cancer NCT05929768
Em recrutamento
Testing the Addition of Pembrolizumab, an Immunotherapy Cancer Drug to Olaparib Alone as Therapy for Patients With Pancreatic Cancer That Has Spread With Inherited BRCA Mutations NCT04548752
Ativo, não recrutando
Ramucirumab and Paclitaxel or FOLFIRI in Advanced Small Bowel Cancers NCT04205968
Em recrutamento
Testing Immunotherapy Versus Observation in Patients With HPV Throat Cancer NCT03811015
Ativo, não recrutando
Testing the Combination of Olaparib and Durvalumab, Cediranib and Durvalumab, Olaparib and Capivasertib, and Cediranib Alone in Recurrent or Refractory Endometrial Cancer Following the Earlier Phase of the Study That Tested Olaparib and Cediranib in Comparison to Cediranib Alone, and Olaparib Alone NCT03660826
Ativo, não recrutandoResultados publicados
Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial NCT04566328
Em recrutamento
A Study to Compare Treatments for a Type of Kidney Cancer Called TFE/Translocation Renal Cell Carcinoma (tRCC) NCT03595124
Ativo, não recrutandoResultados publicados
Pembrolizumab and Dasatinib, Imatinib Mesylate, or Nilotinib in Treating Patients With Chronic Myeloid Leukemia and Persistently Detectable Minimal Residual Disease NCT03516279
Ativo, não recrutando
Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer NCT04181060
Em recrutamento
Testing the Addition of an Antibody to Standard Chemoradiation Followed by the Antibody for One Year to Standard Chemoradiation Followed by One Year of the Antibody in Patients With Unresectable Stage III Non-Small Cell Lung Cancer NCT04092283
Ativo, não recrutando
Testing the Addition of the Pill Chemotherapy, Cabozantinib, to the Standard Immune Therapy Nivolumab Compared to Standard Chemotherapy for Non-small Cell Lung Cancer NCT04310007
Ativo, não recrutando
ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Trastuzumab NCT06876714
Em recrutamento
Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study NCT04269902
Em recrutamento
Pembrolizumab in Treating Patients With Desmoplastic Melanoma That Can or Cannot Be Removed by Surgery NCT02775851
Ativo, não recrutandoResultados publicados
mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma NCT05677490
Em recrutamento
Testing the Addition of a New Anti-cancer Drug, Venetoclax, to Usual Chemotherapy for High Grade B-cell Lymphomas NCT03984448
Ativo, não recrutando
Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With Cabozantinib for Patients With Advanced Kidney Cancer, The PDIGREE Study NCT03793166
Ativo, não recrutando
Nivolumab After Combined Modality Therapy in Treating Patients With High Risk Stage II-IIIB Anal Cancer NCT03233711
Ativo, não recrutando
Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN Study NCT05987241
Em recrutamento
Lenalidomide, and Dexamethasone With or Without Daratumumab in Treating Patients With High-Risk Smoldering Myeloma NCT03937635
Em recrutamento
T-DM1 and Tucatinib Compared With T-DM1 Alone in Preventing Relapses in People With High Risk HER2-Positive Breast Cancer, the CompassHER2 RD Trial NCT04457596
Ativo, não recrutando
Testing MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer NCT02954874
Ativo, não recrutando
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO]) NCT04267848
Em recrutamento
Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer NCT02839707
Ativo, não recrutandoResultados publicados
Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy for HR+/HER2- Locally Recurrent Inoperable or Metastatic Breast Cancer (MK-3475-B49/KEYNOTE-B49) NCT04895358
Ativo, não recrutando
A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or Intolerance to at Least One Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy (KEEPsAKE 1) NCT03675308
Ativo, não recrutandoResultados publicados
Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAFV600 Melanoma NCT02224781
Ativo, não recrutandoResultados publicados
Nivolumab After Surgery and Chemotherapy in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer (An ALCHEMIST Treatment Trial) (ANVIL) NCT02595944
Ativo, não recrutando
Testing the Timing of Pembrolizumab Alone or With Chemotherapy as First Line Treatment and Maintenance in Non-small Cell Lung Cancer NCT03793179
Ativo, não recrutando
Testing the Addition of the Immunotherapy Drug Pembrolizumab to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) in Stage III-IV or Recurrent Endometrial Cancer NCT03914612
Ativo, não recrutandoResultados publicados
Combination Chemotherapy With or Without Ganitumab in Treating Patients With Newly Diagnosed Metastatic Ewing Sarcoma NCT02306161
Ativo, não recrutandoResultados publicados
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors NCT02834013
Ativo, não recrutando
A Comparison of Three Chemotherapy Regimens for the Treatment of Patients With Newly Diagnosed Mantle Cell Lymphoma NCT04115631
Ativo, não recrutando